Financial Ratios Telix Pharmaceuticals Limited
Equities
TLX
AU000000TLX2
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.68 AUD | -0.47% |
|
-5.90% | +31.07% |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | -37.95 | -25.05 | 9.92 | 5.33 | 1.15 | ||||
Return on Total Capital | -118.2 | -96.14 | 25.26 | 7.78 | 1.51 | ||||
Return On Equity % | -198.36 | -253.34 | 4.55 | 13.92 | -1.85 | ||||
Return on Common Equity | -198.36 | -253.34 | 4.55 | 13.92 | -1.85 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 66.46 | 61.55 | 62.56 | 61.79 | 47.51 | ||||
SG&A Margin | 618.56 | 67.76 | 26.63 | 26.45 | 23.96 | ||||
EBITDA Margin % | -1.01K | -42.89 | 11.38 | 11.18 | 4.04 | ||||
EBITA Margin % | -1.01K | -43.15 | 11.19 | 11.03 | 3.57 | ||||
EBIT Margin % | -1.07K | -45.71 | 10.32 | 10.46 | 2.4 | ||||
Income From Continuing Operations Margin % | -1.06K | -65.01 | 1.04 | 6.37 | -0.89 | ||||
Net Income Margin % | -1.06K | -65.01 | 1.04 | 6.37 | -0.89 | ||||
Net Avail. For Common Margin % | -1.06K | -65.01 | 1.04 | 6.37 | -0.89 | ||||
Normalized Net Income Margin | -539.84 | -31.58 | 4.75 | 5.95 | -1.27 | ||||
Levered Free Cash Flow Margin | -492.18 | -18.83 | 12.52 | 11.14 | -4.56 | ||||
Unlevered Free Cash Flow Margin | -490.84 | -18.7 | 12.61 | 11.72 | -3.49 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.06 | 0.88 | 1.54 | 0.81 | 0.76 | ||||
Fixed Assets Turnover | 1.36 | 12.72 | 20.37 | 18.47 | 10.77 | ||||
Receivables Turnover (Average Receivables) | 17.07 | 7.99 | 9.65 | 7.67 | 7.44 | ||||
Inventory Turnover (Average Inventory) | 1.25 | 10.32 | 14.59 | 10.79 | 13.9 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 1.25 | 2.02 | 1.43 | 2.78 | 1.43 | ||||
Quick Ratio | 1.13 | 1.9 | 1.24 | 2.63 | 1.21 | ||||
Operating Cash Flow to Current Liabilities | -1.56 | -0.75 | 0.15 | 0.13 | -0.07 | ||||
Days Sales Outstanding (Average Receivables) | 21.38 | 45.69 | 37.82 | 47.72 | 49.07 | ||||
Days Outstanding Inventory (Average Inventory) | 292.73 | 35.37 | 25.01 | 33.91 | 26.25 | ||||
Average Days Payable Outstanding | 601.38 | 78.64 | 45.99 | 58.05 | 47.74 | ||||
Cash Conversion Cycle (Average Days) | -287.26 | 2.42 | 16.84 | 23.58 | 27.59 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 117.66 | 13.06 | 11.72 | 102.33 | 112.45 | ||||
Total Debt / Total Capital | 54.06 | 11.55 | 10.49 | 50.58 | 52.93 | ||||
LT Debt/Equity | 88.37 | 12.26 | 10.67 | 98.55 | 107.96 | ||||
Long-Term Debt / Total Capital | 40.6 | 10.84 | 9.55 | 48.71 | 50.82 | ||||
Total Liabilities / Total Assets | 98.03 | 68.67 | 62.61 | 62.53 | 64.31 | ||||
EBIT / Interest Expense | -498.45 | -226.56 | 66.18 | 11.3 | 1.4 | ||||
EBITDA / Interest Expense | -466.71 | -209.91 | 74.78 | 12.41 | 2.92 | ||||
(EBITDA - Capex) / Interest Expense | -474.92 | -231.7 | 62.44 | 10.43 | 1.06 | ||||
Total Debt / EBITDA | -0.03 | -0.15 | 0.3 | 6.47 | 11.61 | ||||
Net Debt / EBITDA | 0.26 | 1.56 | -1.8 | -1.43 | 8.08 | ||||
Total Debt / (EBITDA - Capex) | -0.03 | -0.14 | 0.36 | 7.69 | 32.12 | ||||
Net Debt / (EBITDA - Capex) | 0.25 | 1.41 | -2.16 | -1.71 | 22.36 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | 45.71 | 2.01K | 213.9 | 55.85 | 55.61 | ||||
Gross Profit, 1 Yr. Growth % | 58.29 | 1.85K | 231.19 | 58.92 | 19.52 | ||||
EBITDA, 1 Yr. Growth % | 70.73 | -10.51 | -182.16 | 53.18 | -45.57 | ||||
EBITA, 1 Yr. Growth % | 70.7 | -10.36 | -180.32 | 53.66 | -51.29 | ||||
EBIT, 1 Yr. Growth % | 64.96 | -9.93 | -170.02 | 57.83 | -65.49 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | 79.36 | 29.27 | -105.01 | 857.95 | -121.15 | ||||
Net Income, 1 Yr. Growth % | 79.36 | 29.27 | -105.01 | 857.95 | -121.15 | ||||
Normalized Net Income, 1 Yr. Growth % | 59.22 | 23.3 | -146.59 | 95.27 | -132.3 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | 63.02 | 17.44 | -104.81 | 798.14 | -121.62 | ||||
Accounts Receivable, 1 Yr. Growth % | 356.25 | 5.29K | 64.6 | 115.27 | 48.63 | ||||
Inventory, 1 Yr. Growth % | 445.66 | 145.43 | 104.2 | 120.36 | 56.99 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 31.28 | 197.65 | 61.87 | 78.14 | 243.61 | ||||
Total Assets, 1 Yr. Growth % | -30.42 | 132.53 | 55.98 | 273.54 | 23.78 | ||||
Tangible Book Value, 1 Yr. Growth % | -370.19 | -139.24 | 86.69 | 287.48 | -286.63 | ||||
Common Equity, 1 Yr. Growth % | -97.27 | 3.61K | 86.12 | 281.58 | 17.69 | ||||
Cash From Operations, 1 Yr. Growth % | -3.13K | 7.82 | -137.34 | 80.16 | -162.91 | ||||
Capital Expenditures, 1 Yr. Growth % | 439.92 | 425.62 | 37.52 | 47.97 | 181.8 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | 125.97 | -19.38 | -304.76 | 38.74 | -168.28 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 127 | -19.7 | -307.72 | 44.81 | -149.5 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 47.64 | 454.17 | 713.38 | 121.18 | 55.37 | ||||
Gross Profit, 2 Yr. CAGR % | 131.49 | 455.88 | 689.18 | 125.79 | 37.05 | ||||
EBITDA, 2 Yr. CAGR % | 45.46 | 23.61 | -13.68 | 12.19 | -7.78 | ||||
EBITA, 2 Yr. CAGR % | 45.62 | 23.7 | -14.58 | 11.1 | -12.92 | ||||
EBIT, 2 Yr. CAGR % | 42.07 | 21.89 | -20.09 | 5.12 | -25.74 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 69.97 | 52.27 | -74.56 | -30.74 | 30.12 | ||||
Net Income, 2 Yr. CAGR % | 69.97 | 52.27 | -74.56 | -30.74 | 30.12 | ||||
Normalized Net Income, 2 Yr. CAGR % | 50.8 | 40.11 | -23.73 | -4.62 | -20.52 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 54.58 | 38.37 | -76.24 | -34.3 | 27.4 | ||||
Accounts Receivable, 2 Yr. CAGR % | -1.01 | 1.47K | 842 | 88.24 | 71.28 | ||||
Inventory, 2 Yr. CAGR % | 152.44 | 265.95 | 123.87 | 112.13 | 70.62 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 82.56 | 97.67 | 119.5 | 69.81 | 135.43 | ||||
Total Assets, 2 Yr. CAGR % | 3.45 | 27.2 | 90.45 | 143.69 | 104.9 | ||||
Tangible Book Value, 2 Yr. CAGR % | 37.99 | 2.97 | -14.41 | 168.96 | 153.6 | ||||
Common Equity, 2 Yr. CAGR % | -82.45 | 0.63 | 730.69 | 166.5 | 101.16 | ||||
Cash From Operations, 2 Yr. CAGR % | 59.46 | 471.29 | -36.55 | -17.99 | 10.07 | ||||
Capital Expenditures, 2 Yr. CAGR % | 82.28 | 432.72 | 168.86 | 42.65 | 101.83 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 32.91 | 34.97 | 29.71 | 68.55 | -5.72 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 32.96 | 35.01 | 30.39 | 73.44 | -17.84 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 238.99 | 258.15 | 358.52 | 368.92 | 95.98 | ||||
Gross Profit, 3 Yr. CAGR % | 195.82 | 371.18 | 361.96 | 357.68 | 82.02 | ||||
EBITDA, 3 Yr. CAGR % | 40.54 | 23.71 | 8.36 | 4.51 | -11.24 | ||||
EBITA, 3 Yr. CAGR % | 40.75 | 23.88 | 7.59 | 3.89 | -14.97 | ||||
EBIT, 3 Yr. CAGR % | 43.24 | 22.05 | 1.75 | 0.27 | -26.93 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 79.89 | 55.15 | -51.22 | -14.73 | -53.18 | ||||
Net Income, 3 Yr. CAGR % | 79.89 | 55.15 | -51.22 | -14.73 | -53.18 | ||||
Normalized Net Income, 3 Yr. CAGR % | 61.03 | 41.01 | -2.52 | 4.34 | -33.16 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 60.95 | 41.05 | -54.86 | -20.27 | -54.46 | ||||
Accounts Receivable, 3 Yr. CAGR % | 2.49 | 275.21 | 639.78 | 475.92 | 70.1 | ||||
Inventory, 3 Yr. CAGR % | 75.13 | 150.08 | 201.28 | 122.69 | 87.18 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 203.67 | 114.87 | 84.94 | 104.74 | 109.54 | ||||
Total Assets, 3 Yr. CAGR % | 12.7 | 35.51 | 36.15 | 139.91 | 89.77 | ||||
Tangible Book Value, 3 Yr. CAGR % | 58.5 | -9.25 | 25.56 | 41.59 | 133.03 | ||||
Common Equity, 3 Yr. CAGR % | -65.58 | 4.51 | 23.52 | 540.94 | 98.18 | ||||
Cash From Operations, 3 Yr. CAGR % | 41.93 | 39.96 | 130.12 | -10.15 | -26 | ||||
Capital Expenditures, 3 Yr. CAGR % | - | 159.45 | 239.2 | 120.33 | 76.23 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 23.42 | 12.51 | 56.08 | 32.65 | 21.41 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 23.33 | 12.38 | 56.86 | 35.03 | 11.31 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 381.09 | 195.35 | 197.02 | ||||
Gross Profit, 5 Yr. CAGR % | - | - | 338.01 | 248.46 | 182.37 | ||||
EBITDA, 5 Yr. CAGR % | - | 60.16 | 15.65 | 19.28 | 1.6 | ||||
EBITA, 5 Yr. CAGR % | 380.78 | 60.35 | 15.26 | 18.91 | -0.95 | ||||
EBIT, 5 Yr. CAGR % | 385.89 | 62.2 | 13.42 | 15.26 | -10.1 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 349.24 | 74.8 | -17.73 | 12.37 | -24.96 | ||||
Net Income, 5 Yr. CAGR % | 349.24 | 74.8 | -17.73 | 12.37 | -24.96 | ||||
Normalized Net Income, 5 Yr. CAGR % | 331.22 | 66.21 | 19.42 | 20.9 | -9.9 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | 46.4 | -25.13 | 3.9 | -28.97 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | - | 148.91 | 184.74 | 313.62 | ||||
Inventory, 5 Yr. CAGR % | - | - | 93.2 | 134.15 | 144.75 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 411.33 | 166.7 | 95.56 | 104.71 | ||||
Total Assets, 5 Yr. CAGR % | - | 37.96 | 39.02 | 71.37 | 61.71 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | -15.14 | 23.88 | 40.14 | 68.09 | ||||
Common Equity, 5 Yr. CAGR % | - | 10.17 | 22.99 | 51.98 | 51.12 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 60.37 | 2.85 | 13.02 | 67.61 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 316.11 | - | 104.24 | 174.31 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 25.9 | 32.76 | 27.15 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 26.11 | 34.2 | 20.7 |
- Stock Market
- Equities
- TLX Stock
- Financials Telix Pharmaceuticals Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















